Nivolumab-induced interstitial lung disease in a patient with gastric cancer

被引：4

作者：

Kimura, Akie ^{[1
,2
]}

Sakai, Daisuke ^{[1
,2
]}

Kudo, Toshihiro ^{[1
,2
]}

Nishida, Naohiro ^{[1
,2
]}

Katou, Aya ^{[1
,2
]}

Inagaki, Chiaki ^{[1
,2
]}

Otsuru, Toru ^{[1
,2
]}

Miyazaki, Yasuhiro ^{[2
]}

Tanaka, Koji ^{[2
]}

Makino, Tomoki ^{[2
]}

Takahashi, Tsuyoshi ^{[2
]}

Kurokawa, Yukinori ^{[2
]}

Yamasaki, Makoto ^{[2
]}

Mori, Masaki ^{[2
]}

Doki, Yuichiro ^{[2
]}

Satoh, Taroh ^{[1
,2
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, E21-19,2-2 Yamadaoka, Suita, Osaka, Japan

[2] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, E-2,2-2 Yamadaoka, Suita, Osaka, Japan

来源：

OXFORD MEDICAL CASE REPORTS | 2019年 / 02期

关键词：

ADVERSE EVENTS; IMMUNE; ANTIBODY; SAFETY;

D O I：

10.1093/omcr/omz007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We herein report a case of nivolumab-induced interstitial lung disease in a patient with gastric cancer. Nivolumab is a fully human IgG4 monoclonal antibody inhibitor of programmed death-1. A 69-year-old woman with metastatic gastric cancer being treated with nivolumab as fifth-line therapy developed interstitial pneumonia 27 months after starting treatment with nivolumab. Chest computed tomography demonstrated a cryptogenic organizing pneumonia pattern in both lung lobes. This was thought as an immune-related adverse event (irAEs), but stopping the administration of nivolumab failed to resolve the presence of lung shadows. Treatment with steroid pulse therapy twice and subsequently with prednisolone gradually improved the pulmonary function. The administration of high-dose corticosteroid is recommended after the diagnosis of irAEs in nivolumab treatment. Since recovering from pulmonary dysfunction, the patient remains alive with no disease progression. The immediate diagnosis and treatment of irAEs are crucial for achieving a good outcome.

引用

页码：92 / +

页数：4

共 14 条

[1] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[2] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes [J].

Freeman-Keller, Morganna ;

Kim, Youngchul ;

Cronin, Heather ;

Richards, Allison ;

Gibney, Geoffrey ;

Weber, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :886-894

[3] Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review [J].

Friedman, Claire F. ;

Proverbs-Singh, Tracy A. ;

Postow, Michael A. .

JAMA ONCOLOGY, 2016, 2 (10) :1346-1353

[4] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott N. ;

Horn, Leora ;

Gandhi, Leena ;

Spigel, David R. ;

Antonia, Scott J. ;

Rizvi, Naiyer A. ;

Powderly, John D. ;

Heist, Rebecca S. ;

Carvajal, Richard D. ;

Jackman, David M. ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Carbone, David P. ;

Pinder-Schenck, Mary C. ;

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

McDermott, David F. ;

Pardoll, Drew M. ;

Sankar, Vindira ;

Ahlers, Christoph M. ;

Salvati, Mark ;

Wigginton, Jon M. ;

Hellmann, Matthew D. ;

Kollia, Georgia D. ;

Gupta, Ashok K. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2004-U32

[5] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Haanen, J. B. A. G. ;

Carbonnel, F. ;

Robert, C. ;

Kerr, K. M. ;

Peters, S. ;

Larkin, J. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2017, 28 :119-142

[6]

Kang YK, 2017, LANCET, P31827

[7] Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer [J].

Kato, Terufumi ;

Masuda, Noriyuki ;

Nakanishi, Yoichi ;

Takahashi, Masashi ;

Hida, Toyoaki ;

Sakai, Hiroshi ;

Atagi, Shinji ;

Fujita, Shiro ;

Tanaka, Hiroshi ;

Takeda, Koji ;

Satouchi, Miyako ;

Namba, Yoshinobu ;

Tamura, Tomohide .

LUNG CANCER, 2017, 104 :111-118

[8] Consensus statement for the diagnosis and treatment of drug-induced lung injuries [J].

Kubo, Keishi ;

Azuma, Arata ;

Kanazawa, Minoru ;

Kameda, Hideto ;

Kusumoto, Masahiko ;

Genma, Akihiko ;

Saijo, Yasuo ;

Sakai, Fumikazu ;

Sugiyama, Yukihiko ;

Tatsumi, Koichiro ;

Dohi, Makoto ;

Tokuda, Hitoshi ;

Hashimoto, Shu ;

Hattori, Noboru ;

Hanaoka, Masayuki ;

Fukuda, Yuh .

RESPIRATORY INVESTIGATION, 2013, 51 (04) :260-277

[9] Immune-related adverse events with immune checkpoint blockade: a comprehensive review [J].

Michot, J. M. ;

Bigenwald, C. ;

Champiat, S. ;

Collins, M. ;

Carbonnel, F. ;

Postel-Vinay, S. ;

Berdelou, A. ;

Varga, A. ;

Bahleda, R. ;

Hollebecque, A. ;

Massard, C. ;

Fuerea, A. ;

Ribrag, V. ;

Gazzah, A. ;

Armand, J. P. ;

Amellal, N. ;

Angevin, E. ;

Noel, N. ;

Boutros, C. ;

Mateus, C. ;

Robert, C. ;

Soria, J. C. ;

Marabelle, A. ;

Lambotte, O. .

EUROPEAN JOURNAL OF CANCER, 2016, 54 :139-148

[10] Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases [J].

Ohnishi, H ;

Yokoyama, A ;

Kondo, K ;

Hamada, H ;

Abe, M ;

Nishimura, K ;

Hiwada, K ;

Kohno, N .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (03) :378-381

← 1 2 →